351019-18-6

Basic information

• Product Name: 2-Fluoropyridine-5-boronic acid
• Synonyms: RARECHEM AK ML 0441;6-FLUOROPYRIDINE-3-BORONIC ACID;6-FLUOROPYRIDIN-3-YLBORONIC ACID;6-FLUORO-3-PYRIDINYLBORONIC ACID;6-FLUORO-3-PYRIDINEBORONIC ACID;AKOS BRN-0471;(2-FLUOROPYRIDIN-5-YL)BORONIC ACID;2-FLUOROPYRIDINE-5-BORONIC ACID
• CAS NO: 351019-18-6
• Molecular Formula: C₅H₅BFNO₂
• Molecular Weight: 140.91
• EINECS: 1533716-785-6
• Product Categories: HALIDE;PYRIDINE;blocks;BoronicAcids;Pyridines;Boronic Acids & Esters;Heterocyclic Compounds;Fluorinated;Organoborons;Boronic acid;Boronic Acids & Esters;Boronic Acids;Boronic Acids and Derivatives;Heteroaryl;Boronic Acids;Boric acid series
• Mol File: 351019-18-6.mol
• Article Data: 11

Chemical Properties

• Melting Point: 177-178°C (dec.)
• Boiling Point: 311.5 °C at 760 mmHg
• Flash Point: 142.2 °C
• Appearance: white to light yellow solid
• Density: 1.34 g/cm³
• Vapor Pressure: 8.55E-05mmHg at 25°C
• Refractive Index: 1.507
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: 6.97±0.10(Predicted)
• BRN: 8974962
• CAS DataBase Reference: 2-Fluoropyridine-5-boronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Fluoropyridine-5-boronic acid(351019-18-6)
• EPA Substance Registry System: 2-Fluoropyridine-5-boronic acid(351019-18-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36-36/37
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 351019-18-6(Hazardous Substances Data)

Usage

Chemical Properties

white to light yellow solid

Uses

Different sources of media describe the Uses of 351019-18-6 differently. You can refer to the following data:
1. suzuki reaction
2. Used in a synthesis of halohydroxypyridines by hydroxydeboronation with basic hydrogen peroxide.

InChI:InChI=1/C5H5BFNO2/c7-5-3-1-2-4(8-5)6(9)10/h1-3,9-10H

Upstream product

• 171197-80-1 2-fluoro-5-iodopyridine 
• 766-11-0 5-bromo-2-fluoropyridine 
• 121-43-7 Trimethyl borate 
• 504-29-0 2-aminopyridine 
• 20511-12-0 2-amino-5-iodopyridine 

Downstream Products

• 840475-07-2 {1-[3-(6-fluoro-pyridin-3-yl)-phenyl]-ethyl}-carbamic acid tert-butyl ester 
• 55758-32-2 6-fluoropyridin-3-ol 
• 952206-76-7 6-(2,4-dichloro-phenyl)-3-(6-fluoro-pyridin-3-yl)-8-isobutoxy-imidazo[1,2-a]pyridine-7-carbonitrile 
• 945980-25-6 C₁₉H₁₄FNO 
• 1021538-80-6 (4aS,5R)-1-(4-fluorophenyl)-5-(2-(2-(6-fluoropyridin-3-yl)phenyl)ethyl)-4a-methyl-1,4,4a,5,6,7-hexahydrocyclopenta[f]indazol-5-ol 
• 1038395-62-8 4-(2-(4-(6-fluoropyridin-3-yl)phenoxy)ethyl)morpholine 
• 842134-46-7 4-chloro-1-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-3-((5-(6-fluoro-3-pyridyl)-2-thienyl)methyl)benzene 
• 1186110-92-8 1-ethyl-3-(6'-fluoro-4-(4-phenylthiazol-2-yl)-3,3'-bipyridin-6-yl)urea 
• 1208222-42-7 V⁽⁶⁵¹⁾U₀₃₂₁ 
• 1206906-17-3 5-[3,4-bis(2-phenylethynyl)pyridin-2-yl]-2-fluoropyridine 
• 444120-93-8 2-fluoro-5-(4-methoxyphenyl)pyridine 
• 1224952-63-9 C₂₀H₁₃FN₂O₂ 
• 1245737-82-9 8-(6-fluoropyridin-3-yl)-N-[4-(trifluoromethyl)phenyl]-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide 
• 1353754-60-5 C₁₈H₁₄FN₅O₅ 

Relevant articles and documents

PHARMACEUTICAL COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF

The invention relates to a pharmaceutical composition comprising 2-(5-(4-(2- mopholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

Pyrazolo[1,5-a]pyridine antiherpetics: Effects of the C3 substituent on antiviral activity

A recently disclosed series of pyrazolo[1,5-a]pyridine inhibitors of herpes virus replication has been closely examined herein for effects of the C3 substituent on antiviral activity. Significant changes in activity are observed by alterations of the hete

SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER

Disclosed are nicotine-related compounds that selectively inhibit cytochrome P-450 2A6 (CYP2A6), selectively inhibit cytochrome P-450 2A13 (CYP2A13), and/or selectively modulate a nicotinic acetylcholine receptor (nAChR). Also disclosed are pharmaceutical compositions comprising a compound of the invention, as well as methods of using the pharmaceutical compositions for treating or preventing a disease or disorder associated with nicotine-ingestion, or a disease or disorder amenable to treatment by selective modulation of nAChRs.